WISE Closes €30M Series D to Advance Heron Lead for Spinal Cord Stimulation
WISE, an Italy-based medical device company specializing in advanced implantable electrodes for neuromonitoring, neuromodulation, and brain-computer interfaces (BCI), has announced the closing of an oversubscribed Series D financing round totaling €30 million led by ENEA Tech and Biomedical, an Italian foundation dedicated to innovation and technology transfer in the biomedical sector. This final closing builds on the first closing of the round completed in June 2024, which included a venture debt facility from the European Investment Bank supported by InvestEU, alongside an equity investment from Wallaby S.p.A. and existing financial partners.
The primary use of the proceeds is to advance the development and clinical adoption of the Heron lead, WISE’s flagship product for spinal cord stimulation (SCS). The Heron lead is the first SCS lead designed to deliver targeted, directional stimulation through a minimally invasive percutaneous implant technique, uniquely combining the therapeutic precision of surgical paddle leads with the lower procedural burden of cylindrical leads. This dual advantage translates into higher energy efficiency, better anatomical coverage, improved neural signal sensing, and reduced lead migration. Proceeds will fund the Heron lead’s regulatory certification pathway and first-in-human study, while also driving the commercial scale-up of WISE’s full electrode portfolio.
WISE’s proprietary Supersonic Technology enables the production of implantable electrodes and BCI systems consisting of stretchable electronic circuits integrated into ultra-thin elastomeric foils. Compared to conventional rigid electrodes, WISE’s devices deliver superior tissue conformability, softness, and adhesion, which are critical to both safety and therapeutic efficacy.
The round will also support expanded commercialization of the WISE Cortical Strip, the first soft, stretchable electrode for intraoperative neurophysiological monitoring during brain tumor and epilepsy surgeries, which holds CE mark under MDR and FDA clearance.
The closing also brings the appointment of Laura Iris Ferro as Chairperson and Giuseppe Corvino to the Board of Directors. Luca Ravagnan, Chief Executive Officer of WISE, stated that the oversubscription of the round is a testament to the strength of what the team has built in technology, medical research, and relationships with clinicians and partners, adding that with the Heron lead, the company is targeting a multi-billion-euro market with a product that addresses a long-lasting unmet clinical need.
